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What is HIV‐1?
• HIV-1 is an epidemic that affects 
over 34 million people worldwide. 
• HIV-1 causes disease by attacking 
CD4 T-cells, which are essential to a 
healthy immune system. 
• Viral glycoproteins on the surface 
on the viral envelope are the 
proteins the virus uses to enter and 
infect these T-cells. 
• These viral glycoproteins consists of 
two non-covalently bonded 
subunits: gp120 and gp41, which 
associate as a heterotrimer.
• gp120 binds to the CD4 cell 
receptor inducing a conformation 
change exposing the coreceptor
binding site. 
http://www.niaid.nih.gov/topics/hivaids/understanding/biology/Pages/structure.aspx
http://www.sciencemag.org/content/320/5877/760.figures‐only
HIV‐1 fusion and entry
• Once the gp120 subunit binds to the 
coreceptor, the gp41 subunit is 
exposed and undergoes a 
conformational change, unfolding 
and inserting into the host cell 
membrane. 
• Once the gp41 subunit trimer is 
inserted, a cluster of two trimer
prehairpins form. 
• gp41 trimers then fold onto 
themselves creating a hairpin-like six 
helix bundle. 
• Trimeric hairpins bring the 
membranes together, causing the 
outer membranes to fuse in 
hemifusion and the inner membrane 
to fuse, completely joining the two.
• The capsid is then free to enter the 
host cell http://people.virginia.edu/~jw7g/Website%2009%20Updates/Fusn_Modl09.png
Why hasn’t a vaccine been developed yet?
• Because of the nature of these 
glycoproteins, it is very hard to 
establish a vaccine that will cause 
the production of broadly 
neutralizing antibodies (bnAb)
• Both gp120 and gp41 are highly 
variable
• Glycosylation on gp120 protects 
conserved epitopes on both gp120 
and gp41
• The heavy glycosylation also forms a 
cage-like structure around the gp41 
trimer, causing the gp41 subunit to 
be very difficult to access. 
• This protection restricts antibody 
access to the gp41 region, which 
provides a difficulty when producing 
a suitable vaccine. 
http://www.nature.com/nsmb/journal/v20/n12/full/nsmb.2711.html
http://home.ccr.cancer.gov/inthejournals/subramaniam.asp
Some strains can be neutralized!
• Even though it is difficult, 
several antibodies have been 
isolated from patients that 
can neutralize a broad range 
of HIV to a varying degree of 
success.
• These  antibodies include 2F5, 
4e10, and 10e8, which all 
target the MPER in gp41.
• The most easily neutralized 
strains are tier 1 viruses. These 
viruses have typically been 
passaged in laboratories for 
easy use.
• Tier 2 and tier 3 viruses are 
harder to neutralize, but are 
the type of viruses that are 
found in most patients. https://www.aidsreagent.org/program_info.cfm
So why can some strains be neutralized?
• Our lab focuses mainly on gp41 for several reasons:
o gp41 is more highly conserved and the known bnAbs are 
concentrated in a very small region (MPER). 
o This small region allows for a minimization of the vaccine 
candidate size, which can also limit the amount of non-
neutralizing antibodies produced.
• We would like to understand why tier 2 viruses are more difficult 
to neutralize with gp41-targeting bnAbs than tier 1 viruses.
• The information that will be gathered from this study has the 
potential to shed light on the biological reasons that tier 2 
viruses are more resistant than tier 1 viruses. 
• If we are able to to understand how these differences prevent 
neutralizing antibodies from binding, we may be able to 
produce better immunogens able to guide the immune system 
to overcome these resistance-inducing mutations
• For this study, we used MN (tier 1, sensitive) and 6535 (tier 2, 
resistant) as representative viral strains
Original HIV‐1 Envelope sequences
6535 (tier 2)= resistant to neutralization
MN (tier 1A)= Sensitive to neutralization
• Previous work identified a region of the gp41 envelope 
sequence that determined whether the strain was sensitive 
or resistant to neutralization
• This was accomplished by producing several chimera viruses 
using laboratory techniques such as digestion and ligation. 
• Digestion was done using appropriate restriction sites to 
digest the original sequences into the desired fragments.
• Once the specific fragments were produced, ligation was 
used to create the following chimera viruses, which were 
used to narrow down the region in which the change(s) 
affecting neutralization resistance is located. 
6535mMN:
• 6535 at the gp120 region, breaks at the Mfel restriction site. The chimera is then MN 
at the gp41 region. 
• We originally hypothesized that this chimera would be resistant, since the gp120 
region should block access to the gp41 region of interest. 
MfeI
6535hMN:
• 6535 at the gp120 region and the N terminus of the gp41 region, which includes the 
fusion peptide, N-heptad repeat and part of the C-heptad, of gp41. 
• This breaks at the HindIII restriction site with the rest of the gp41 region represented by 
the MN strain. 
HindIII
6535aMN: AvrII
• 6535 at the gp120 region and a small portion of the N terminus of gp41, which breaks 
at the AvrII restriction site. The remaining gp41 region is represented by the MN strain.
• It is important to note that in all three chimeras, the epitope that the brNabs bind to is 
always derived from the sensitive MN strain. 
gp120 gp41
V2 V3 V5 MPERV4V1
Pseudoviruses
• We do not work with infectious HIV-1 viral particles in the lab
• HIV-1 pseudoviruses infect a cell exactly like how HIV would normally 
infect, but when it comes to spreading and infecting more cells, it 
cannot.
• Pseudovirus genomes consist of two plasmids: 
o One plasmid contains everything except the envelope gene
o The second plasmid contains only the envelope gene, but 
without the packaging signal.
• Without the packaging signal, the envelope gene is not packaged 
into the virion, so the virus cannot form an envelope and spread to 
other cells. 
• Pseudoviruses produced for each mutant HIV-1 envelope genome, 
are used in neutralization assays, which measure the percent of 
neutralization different antibodies (2F5, 4e10, and 10e8) are able to 
produce. 
http://www.yale.edu/bio243/HIV/genome.gi
Neutralization Assays
• Tzm‐bl cells are used in these assays.
o Tzm‐bl cells are HeLa derived cells that express the CD4 receptor and the 
two coreceptors CCR5 and CXCR4, which allow the HIV pseudovirus to 
enter and infect the cells. 
o The cells also have a genetic insert that expresses B‐galactosidase and 
luciferase , which are under the control of an HIV induced promoter.
o Only when HIV is present, does the promoter turn on and drive B‐
galactosidase and luciferase expression. 
• To perform this assay, a known amount of pseudovirus and several serial 
dilutions of monoclonal antibodies (mAb) are co‐incubated without cells for 
one hour, giving the antibodies a chance to bind and neutralize the 
pseudovirus.
• Tzm‐bl cells are then added to the pseudovirus and mAbs, and incubated for 
two days.
• To measure the amount of pseudovirus neutralized by the mAbs, luciferin is 
added, which will be cleaved by the luciferase enzyme and create a visible 
light signal.
o This is measured in reflective light units (RLU).
Neutralization assays
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• These two graphs show the 
neutralization curve using the 
antibodies 2F5 and 10e8. 
• The viral strain MN.3 (dark blue), 
and mutants 6535mMN (green) 
and 6535aMN (light blue) show 
neutralization sensitivity to both 
2F5 and 10e8 antibodies
• The viral strains 6535 (red) and the 
mutant 6535hMN (purple) both 
show neutralization resistance to 
both 2F5 and 10e8 antibodies. 
• These results would be reported 
as the point where the 
neutralization reaches 50%. 
• These neutralization sensitive viral 
strains require a much lower 
amount of antibody for 
neutralization compared to the 
neutralization resistant strains. 
Neutralization assay results
• Neutralization did occur in 6535mMN even though the gp120 was 
from the resistant strain, so gp120 had no effect on the 
neutralization 
• MNm6535 remains resistant to neutralization confirms that the 
determining factor of sensitivity vs. resistance between these two 
strains to neutralization is located in the gp41 subunit
• 6535aMN and 6535hMN further narrow the region resulting the in 
difference between neutralization sensitivity
gp120 gp41
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Possible mutations affecting the neutralization 
resistance of HIV‐1 6535 and MN strains
6535aMN: AvrII
Region of interest
There are seven possible mutation within this region:
6535mMN: MfeI
6535hMN: HindIII
MN:
6535:
HindIII
AvrII
MN:
6535:
MN:
6535:
gp120 gp41
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Site directed mutagenesis 
• Site directed mutagenesis allowed us to mutate a 
single amino acid to test whether or not each 
mutation affects the neutralization resistance of 
the virus. 
• The first step is a simple PCR reaction with minor 
alteration and primers with a mismatched base 
pair to the original template DNA at the site of the 
desired mutation. 
• This PCR reaction produces the desired mutant 
strand.  
• The remaining parent strand is removed by 
digestion with Dpn1, which only targets 
methylated DNA. 
• The final product is just the mutant strand, which is 
then transformed into competent cells that are 
able to repair the nick remaining from the linear 
PCR product. 
• Extraction of the mutated genome is done, and a 
neutralization assay can then be performed using 
pseudoviruses expressing the mutated genome. 
http://www.genomics.agilent.com/files/Media/Pid24_P2.jpg
Production of Mutant Pseudovirus
• Before performing a neutralization assay, mutant pseudoviruses must be 
produced for each site directed mutant. 
• However, when measuring the titers of the produced pseudoviruses we 
discovered that we did not have high enough yields to perform a 
neutralization assay.  
Lanes 1 2 3 4 5 11
Mutant T607A A612T D620N D621Y 6535 wild
type
Negative
control
RLU per 25uL 2184 1309 446 1125 708 397
• The minimum reflective light units (RLU) needed to perform a 
neutralization assay is a 10 fold over the background.
• The background is 397 RLU per 25uL, so the minimum titer needed is about 
4,000 RLU per 25uL
• These low numbers may be the result of poor cell quality during and after 
transfection. 
MN:
6535:
AvrII HindIII
T607A D621YD620NA612T
Future Directions and Applications
• Currently we have confirmed the sequences of 5 out of the 7 
possible mutants. These other two mutants will be confirmed as 
well
• We must still complete the pseudovirus production of all mutants, 
which will then be tested and assayed. 
• The information that will be gathered from this study has the 
potential to shed light on why tier 2 viruses are more difficult to 
neutralize than tier 1 viruses. 
• The differences responsible for the difference in neutralization 
resistance between viral strains MN and 6535 may be one of many 
mutations affecting resistance to gp41 targeting antibodies.
o Multiple differences may act together to induce resistance.
• If we are able to to understand how these differences prevent 
neutralizing antibodies from binding, we may be able to produce 
better immunogens able to guide the immune system to 
overcome these resistance-inducing mutations
Thank you!
